Salarius Pharmaceuticals, Inc. (SLRX)
| Market Cap | 53.73M |
| Revenue (ttm) | 5.37M |
| Net Income (ttm) | -7.52M |
| Shares Out | 30.55M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 15 |
| Last Price | $1.20 |
| Previous Close | $1.21 |
| Change ($) | -0.01 |
| Change (%) | -0.83% |
| Day's Open | 1.21 |
| Day's Range | 1.18 - 1.23 |
| Day's Volume | 1,471,590 |
| 52-Week Range | 0.63 - 3.50 |
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an ope...
Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to targ...
Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone dem...
Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial
Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials
Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 72.73% year over year to ($0.06), which mis...
Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET
HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 77.27% over the past year to ($0.10)...
Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET
Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors,...
HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q3 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET
Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET
HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Execu...
Presentations Will Highlight Corporate and Clinical Progress Presentations Will Highlight Corporate and Clinical Progress
Webcast presentation scheduled for Tuesday, September 1, 2020 Webcast presentation scheduled for Tuesday, September 1, 2020
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2020 Results - Earnings Call Transcript
Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas
Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET
New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced th...
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced ...
Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas Pre-Clinical Data and Early Clinical Observations...
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2020 Results - Earnings Call Transcript
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020
Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director Board of Directors Seeks the Election of Jonathan...
European Patent Office Satisfied Patent Application Meets All Requirements
HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced th...
HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an...
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, ... [Read more...]
| Industry Biotechnology | |
| CEO David Arthur | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol SLRX |
Financial Performance
In 2020, SLRX's revenue was $5.23 million, an increase of 51.03% compared to the previous year's $3.47 million. Losses were -$7.35 million, 6.00% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.10, which is an increase of 241.67% from the latest price.